CLOV · Clover Health Investments, Corp. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-10-20 | Soares Karen |
Chief Legal Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 13, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.45 to $4.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
19,275 |
| 2026-10-19 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.32 to $4.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
4,066 |
| 2026-10-15 | THORNTON JOSEPH CLAY |
Interim CFO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on October 15, 2026. The RSUs were originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
4,591 |
| 2026-10-15 | Wai Conrad |
CEO, Counterpart Health |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
23,627 |
| 2026-10-15 | Toy Andrew |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting on October 15, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on October 15, 2024. The restricted stock units vest quarterly, with a final vesting on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
62,176 |
| 2026-10-15 | Soares Karen |
Chief Legal Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting on October 15, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on October 15, 2024. The restricted stock units vest quarterly, with a final vesting on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
14,673 |
| 2026-10-15 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting on October 15, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on October 15, 2024. The restricted stock units vest quarterly, with a final vesting on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
18,273 |
| 2026-10-07 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.54 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
2,006 |
| 2026-10-05 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting of 6.25% of restricted stock units (the "RSUs") on October 3, 2026. The RSUs were originally granted to the Reporting Person on January 3, 2023, with a final vesting on January 3, 2027, subject to the continued service of the Reporting Person on such final vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Class A Common Stock
|
8,750 |
| 2026-10-01 | Toy Andrew |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting on October 1, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on January 1, 2023. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
318,806 |
| 2026-09-30 | Torricelli Robert G |
Director |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A common stock of Clover Health Investments, Corp. (the "Company") underlying a time-based restricted stock unit award ("RSUs") granted to the Reporting Person on September 30, 2026. The RSUs will vest in full on the first anniversary of September 30, 2026 subject to the Reporting Person's continued service as a member of the Company's Board of Directors through such vesting date. |
Class A Common Stock
|
12,481 |
| 2026-09-30 | Miller Brian James |
Director |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A common stock of Clover Health Investments, Corp. (the "Company") underlying a time-based restricted stock unit award ("RSUs") granted to the Reporting Person on September 30, 2026. The RSUs will vest in full on the first anniversary of September 30, 2026 subject to the Reporting Person's continued service as a member of the Company's Board of Directors through such vesting date. |
Class A Common Stock
|
12,481 |
| 2026-09-17 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. |
Class A Common Stock
|
1,921 |
| 2026-09-16 | OLDAKOWSKI JOSEPH FRANK |
VP OF FINANCE AND CONTROLLER |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on June 16, 2025. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on June 16, 2029, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Class A Common Stock
|
3,170 |
| 2026-09-15 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the final 6.25% of restricted stock units (the "RSUs") on September 15, 2026. The RSUs were originally granted to the Reporting Person on September 16, 2022. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
9,273 |
| 2026-09-15 | Soares Karen |
Chief Legal Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the final vesting of 6.25% of restricted stock units originally granted to the Reporting Person on September 15, 2022. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
6,846 |
| 2026-09-15 | Wai Conrad |
CEO, Counterpart Health |
Sell↓
Filing footnotes — Class A Common Stock (Indirect)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.60 to $5.06, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee. |
Class A Common Stock
(I)
|
300,000 |
| 2026-09-14 | OLDAKOWSKI JOSEPH FRANK |
VP OF FINANCE AND CONTROLLER |
Sell↓
|
Class A Common Stock
|
20,000 |
| 2026-08-17 | THORNTON JOSEPH CLAY |
Interim CFO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on August 16, 2026. The RSUs were originally granted to the Reporting Person on February 16, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on February 16, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.29 to $4.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
17,775 |
| 2026-08-12 | Soares Karen |
Chief Legal Officer |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A common stock underlying a time-based restricted stock unit award ("RSUs"). Twenty-five percent of the RSUs will vest on the first anniversary of August 12, 2026, and the remaining RSUs will vest in twelve equal quarterly installments beginning on the date that is three months after the first anniversary of August 12, 2026, in each case subject to the continued service of the Reporting Person on each such vesting date, so that such RSUs will be fully vested on August 12, 2030. |
Class A Common Stock
|
108,695 |
| 2026-08-12 | THORNTON JOSEPH CLAY |
Interim CFO |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A common stock underlying a time-based restricted stock unit award ("RSUs"). Twenty-five percent of the RSUs will vest on the first anniversary of August 12, 2026, and the remaining RSUs will vest in twelve equal quarterly installments beginning on the date that is three months after the first anniversary of August 12, 2026, in each case subject to the continued service of the Reporting Person on each such vesting date, so that such RSUs will be fully vested on August 12, 2030. |
Class A Common Stock
|
54,347 |
| 2026-08-10 | Toy Andrew |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the final vesting on August 8, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on August 8, 2022. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.61 to $4.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
87,798 |
| 2026-07-20 | Soares Karen |
Chief Legal Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 13, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
51,700 |
| 2026-07-17 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.35 to $4.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
4,839 |
| 2026-07-15 | Wai Conrad |
CEO, Counterpart Health |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
24,215 |
| 2026-07-15 | Toy Andrew |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
62,711 |
| 2026-07-15 | Soares Karen |
Chief Legal Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
10,519 |
| 2026-07-15 | THORNTON JOSEPH CLAY |
Interim CFO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on July 15, 2026. The RSUs were originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
4,630 |
| 2026-07-15 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on July 15, 2026. The RSUs were originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
13,119 |
| 2026-07-08 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. |
Class A Common Stock
|
2,384 |
| 2026-07-06 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on July 3, 2026. The RSUs were originally granted to the Reporting Person on January 3, 2023. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on January 1, 2027, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Class A Common Stock
|
6,229 |
| 2026-07-01 | Toy Andrew |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on January 1, 2023. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on January 1, 2027, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Class A Common Stock
|
313,476 |
| 2026-06-17 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $4.87, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks: |
Class A Common Stock
|
2,360 |
| 2026-06-16 | OLDAKOWSKI JOSEPH FRANK |
VP OF FINANCE AND CONTROLLER |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25% of restricted stock units ("RSUs") originally granted to the Reporting Person on June 16, 2025. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on June 16, 2029, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Class A Common Stock
|
12,102 |
| 2026-06-15 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.61 to $4.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
6,350 |
| 2026-06-15 | Soares Karen |
Chief Legal Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.61 to $4.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Class A Common Stock
|
4,681 |
| 2026-06-11 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.15, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks: |
Class A Common Stock
|
7,289 |
| 2026-05-28 | Wai Conrad |
CEO, Counterpart Health |
Sell↓
Filing footnotes — Class A Common Stock (Indirect)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $3.92 to $4.04, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee. |
Class A Common Stock
(I)
|
220,426 |
| 2026-05-18 | Edwards Carladenise Armbrister |
Director |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
67,160 |
| 2026-05-16 | THORNTON JOSEPH CLAY |
Interim CFO |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on May 16, 2026, due to the vesting of 6.25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on February 16, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on February 16, 2028, subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
16,942 |
| 2026-05-13 | Priest Brady Patrick |
CEO of Clover Care Services |
Sell↓
|
Class A Common Stock
|
98,039 |
| 2026-05-08 | Toy Andrew |
Director, Chief Executive Officer |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations upon the vesting, on May 8, 2026, of 6.25% of the original number of time-based restricted stock units ("RSUs") granted to the Reporting Person on August 8, 2022, and timely reported on a Form 4 filed on August 10, 2022. The remaining RSUs vest quarterly in equal installments of 6.25%, with a final vesting date occurring on August 8, 2026, subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
85,704 |
| 2026-04-18 | Priest Brady Patrick |
CEO of Clover Care Services |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations upon the vesting, on April 18, 2026, of 6.25% of the original number of time-based restricted stock units ("RSUs") granted to the Reporting Person on July 18, 2022, and timely reported on a Form 4 filed on July 19, 2022. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on July 18, 2026, subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
36,113 |
| 2026-04-15 | Wai Conrad |
CEO, Counterpart Health |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on April 15, 2026, due to the vesting of 6.25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024, and timely reported on a Form 4 filed on October 17, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
23,463 |
| 2026-04-15 | Toy Andrew |
Director, Chief Executive Officer |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on April 15, 2026, due to the vesting of 6.25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024, and timely reported on a Form 4 filed on October 17, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
60,765 |
| 2026-04-15 | Priest Brady Patrick |
CEO of Clover Care Services |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on April 15, 2026, due to the vesting of 6.25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024, and timely reported on a Form 4 filed on October 17, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
15,471 |
| 2026-04-15 | Soares Karen |
Chief Legal Officer |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on April 15, 2026, due to the vesting of 6.25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024, and timely reported on a Form 4 filed on October 17, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
10,161 |
| 2026-04-15 | THORNTON JOSEPH CLAY |
Interim CFO |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on April 15, 2026, due to the vesting of 6.25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
4,158 |
| 2026-04-15 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on April 15, 2026, due to the vesting of 6.25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024, and timely reported on a Form 4 filed on October 17, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
12,712 |
| 2026-04-03 | Reynoso Jamie L. |
CEO, Medicare Advantage |
Tax↓
Filing footnotes — Class A Common Stock (Direct)
Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations due to the vesting on April 3, 2026, of 6.25% of the restricted stock units ("RSUs") granted to the Reporting Person on January 3, 2023, and originally reported on a Form 4 filed on January 5, 2023. The remaining RSUs will vest in equal quarterly installments, with the final vesting occurring on January 3, 2027, in each case subject to the continued service of the Reporting Person on each such vesting date. |
Class A Common Stock
|
6,197 |